First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer.

Prostate-specific antigen (PSA) doubling time is relying on an exponential kinetic pattern. This pattern has never been validated in the setting of intermittent androgen deprivation (IAD). Objective is to analyze the prognostic significance for PCa of recurrent patterns in PSA kinetics in patients undergoing IAD.

A retrospective study was conducted on 377 patients treated with IAD. On-treatment period (ONTP) consisted of gonadotropin-releasing hormone agonist injections combined with oral androgen receptor antagonist. Off-treatment period (OFTP) began when PSA was lower than 4 ng/ml. ONTP resumed when PSA was higher than 20 ng/ml. PSA values of each OFTP were fitted with three basic patterns: exponential (PSA(t) = λ. e(αt) ), linear (PSA(t) = a. t), and power law (PSA(t) = a. t(c) ). Univariate and multivariate Cox regression model analyzed predictive factors for oncologic outcomes.

Only 45% of the analyzed OFTPs were exponential. Linear and power law PSA kinetics represented 7. 5% and 7. 7%, respectively. Remaining fraction of analyzed OFTPs (40%) exhibited complex kinetics. Exponential PSA kinetics during the first OFTP was significantly associated with worse oncologic outcome. The estimated 10-year cancer-specific survival (CSS) was 46% for exponential versus 80% for nonexponential PSA kinetics patterns. The corresponding 10-year probability of castration-resistant prostate cancer (CRPC) was 69% and 31% for the two patterns, respectively. Limitations include retrospective design and mixed indications for IAD.

PSA kinetic fitted with exponential pattern in approximately half of the OFTPs. First OFTP exponential PSA kinetic was associated with a shorter time to CRPC and worse CSS. Prostate © 2015 Wiley Periodicals, Inc.

The Prostate. 2015 Oct 26 [Epub ahead of print]

Rafael Sanchez-Salas, Fabien Olivier, Dominique Prapotnich, José Dancausa, Mehdi Fhima, Stéphane David, Fernando P Secin, Alexandre Ingels, Eric Barret, Marc Galiano, François Rozet, Xavier Cathelineau

Department of Urology, Institut Mutualiste Montsouris, Paris, France. , Altran Research, Altran France, Velizy-Villacoublay, France. , Department of Urology, Institut Mutualiste Montsouris, Paris, France. , Altran Research, Altran France, Velizy-Villacoublay, France. , Altran Research, Altran France, Velizy-Villacoublay, France. , Altran Research, Altran France, Velizy-Villacoublay, France. , Urology Section, CEMIC and San Lazaro Foundation, Buenos Aires, Argentina. , Department of Urology, Institut Mutualiste Montsouris, Paris, France. , Department of Urology, Institut Mutualiste Montsouris, Paris, France. , Department of Urology, Institut Mutualiste Montsouris, Paris, France. , Department of Urology, Institut Mutualiste Montsouris, Paris, France. , Department of Urology, Institut Mutualiste Montsouris, Paris, France.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe